CD226 and neoplasm: These include NKG2D, FCγIII (CD16), FasL, TRAIL and DNAM‐1 (CD226).61, 62, 63, 64, 65 Vγ9+Vδ2+ T cells recognise tumor‐derived phosphorylated prenyl metabolites in a TCR‐dependent manner, which may accumulate intracellularly as a by‐product of dysregulated tumor metabolism (Figure 1).